FreeTheAI

DataMeds AI Secures Exclusive Rights to REBOOT Technology for Weight Loss Services

MixedMedium impact
MEDS$2.63 −7.72%

DataMeds AI, Inc. (MEDS) has agreed to a deal with REBOOT Health AI to bring artificial intelligence capabilities to its direct-to-consumer weight care products. Under the contract, the business gains sole rights within the United States to adapt and run the software for its appetite-suppressing medication offerings. Following the news, shares of DataMeds AI fell 7.72% to finish at $2.63.

To compensate REBOOT Health AI, DataMeds AI issued 666,667 equity units carrying trading restrictions, calculated at $2.0 million with a potential price adjustment after 180 days. The deal, which went into effect on October 13, 2026, also involves splitting generated income and contributing $50,000 toward setting up the software, an overhaul projected to cost at least $100,000. The arrangement remains in place until the final related patent terminates, while placing limits on editing or inspecting the underlying computer code.

This transaction allows DataMeds AI to bolster its weight management operations using established software tools without building the underlying framework internally. Market participants will likely watch how efficiently the platform is customized, whether the consumer appetite-control division generates expected returns, and if the six-month stock price evaluation alters the total share count.

Key points

  • DataMeds AI, Inc. (MEDS) obtained sole U.S. rights to REBOOT Health AI software to support its consumer GLP-1 weight care business.
  • Payment involves 666,667 restricted equity shares worth $2.0 million with a six-month price balancing clause, plus income sharing.
  • DataMeds AI will pay $50,000 for software setup, with overall adaptation expenses anticipated to reach at least $100,000.
  • The agreement stays active until the last patent terminates and limits changes to the underlying source code.
  • Shares of DataMeds AI fell 7.72% to $2.63 following the update.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What deal did DataMeds AI make with REBOOT Health AI?

DataMeds AI obtained sole U.S. rights to use and customize REBOOT's artificial intelligence tools for its consumer GLP-1 weight management business.

What is DataMeds AI paying for the technology rights?

The company provided 666,667 restricted shares worth $2.0 million with a 180-day price evaluation, plus $50,000 for technical setup and ongoing revenue sharing.

How long is the agreement between the two companies?

The licensing terms stay in effect indefinitely until the expiration of the final covered patent.